Loading data for ENTA — first visit, this takes a few seconds.

Enanta Pharmaceuticals In...

NasdaqGS: ENTA · Real-Time Price · USD
13.60
-0.20 (-1.45%)
At close: Aug 28, 2026, 3:59 PM
13.60
+0.00%
After-hours: 7:30 PM

The price, the headline numbers and the latest news, in one place.

Enanta Pharmaceuticals Inc. (ENTA) Stock Price, Analysis & Data

-1.45%
Bid13.62
Market Cap396.11M
Revenue (ttm)65.26M
Net Income (ttm)-63.23M
0.93
-2.39
n/a
-5.38
P/B (ttm)3.92
P/S (ttm)6.07
Earnings DateNov 16, 2026
Ask17.24
Volume155,913
Avg. Volume (20D)213,787
Open13.91
Previous Close13.80
Day's Range13.48 - 13.91
52-Week Range7.05 - 17.15
Analystn/a
Price Targetn/a
Dividendsn/a
Ex-Dividend Daten/a

About ENTA

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II c...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 21, 2013
Employees 120
Stock Exchange NasdaqGS
Ticker Symbol ENTA
Full Company Profile

Financial Performance

In 2025, Enanta Pharmaceuticals's revenue was 65.32M, a decrease of -3.42% compared to the previous year's 67.64M. Earnings were -81.89M, a decrease of -29.43%.

Financial Statements

Earnings Surprise

Enanta Pharmaceuticals has released their quarterly earnings on Aug 10, 2026:
  • Revenue of $17.16M misses estimates by $0, with 14.96% YoY growth.
  • EPS of -0.67 misses estimates by -0.16, with 21.18% YoY growth.
Enanta Pharmaceuticals Inc. is scheduled to release its earnings on Nov 16, 2026, during market hours.
Analysts project revenue of ... Upgrade
Page 1 of 2